During the past decade, a number of cephalosporins with broad spectra of activity and resistance to hydrolysis by ,-lactamases have been developed. However, the clinical usefulness of these antibiotics has been limited because of their rather weak activities against Staphylococcus species and Pseudomonas aeruginosa (14) and the rapid development of resistance in some gram-negative bacilli, such as Citrobacter, Enterobacter, and Serratia species (11, 22) .
In the course of modifications of cephalosporins aimed at improving their activity, SCE-2787, 713-[2-(5-amino-1,2,4-thiadiazol -3 -yl) -2(Z) -methoxyiminoacetamido] -3 -(imidazo-[1 ,2-b]pyridazinium -1 -yl)methyl-3 -cephem -4-carboxylate, inner salt hydrochloride, has been found to be highly active against not only members of the family Enterobacteriaceae, including strains resistant to ceftazidime, but also staphylococci and Pseudomonas aeruginosa (12) . Its chemical structure ( Fig. 1 ) is characterized by a condensed azolium moiety in the 3 position and an aminothiadiazolyl group in the 7, side chain of a cephalosporin.
In this report, we describe the in vitro and in vivo activities of SCE-2787 in comparison with those of ceftazidime (17) , flomoxef (25) , cefpirome (23) , and E1040 (26) . We also report the interaction of SCE-2787 and the reference 1-lactam antibiotics with various types of 3-lactamases, including the Bush group 1 ,B-lactamases.
(A part of this work was presented at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Tex., 17 to 20 September 1989 [7] .) * Corresponding author.
MATERIALS AND METHODS
Antibiotics. SCE-2787, cefpirome, and E1040 were synthesized in the Research and Development Division, Takeda Chemical Industries Ltd., Osaka, Japan. Other antibacterial agents were purchased commercially, as follows: ceftazidime, Nippon Glaxo Co., Ltd., Tokyo, Japan; flomoxef and cephaloridine, Shionogi and Co., Ltd., Osaka, Japan; methicillin, Banyu Pharmaceutical Co., Ltd., Tokyo, Japan; and benzylpenicillin (Meiji Seika Kaisha, Ltd., Tokyo, Japan).
Organisms. The clinical isolates used in this study were kindly supplied by five clinical laboratories in Japan between 1987 and 1988 and were maintained in our laboratory. Laboratory standard strains were obtained from our culture collection.
Determination of MICs and MBCs. Mueller-Hinton broth (BBL Microbiology Systems, Cockeysville, Md.) or Mueller-Hinton agar (BBL) was used for all assays except the following. For Streptococcus species and Corynebactenium diphtheriae, Mueller-Hinton broth or Mueller-Hinton agar was supplemented with 10% horse serum. Haemophilus influenzae was tested with brain heart infusion (BHI; Difco Laboratories, Detroit, Mich.) supplemented with 5% Fildes enrichment (Difco). Bordetella pertussis was tested with Iso-Sensitest agar (Oxoid, Basingstoke, United Kingdom) supplemented with 5% bovine blood. For anaerobes, GAM agar (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) was used. Trypticase soy agar (BBL), nutrient agar (Eiken Chemical Co., Ltd., Tokyo, Japan), BHI agar (Difco), and heart infusion agar (Difco) were also used to examine the effect of culture medium. Bacterial suspensions for inocula were prepared by diluting overnight cultures of the organisms to be tested in the fresh broth medium to give the desired concentrations.
The MICs by the microbroth dilution method were deter- (19) . Briefly, about 5 x 105 CFU of organisms to be tested were inoculated into 0.8 ml of Trypticase soy broth (BBL) containing twofold serial dilutions of an antibiotic in glass tubes. After the MIC was determined, the cultures were diluted 10-fold with 0.9% saline, and 0.1-ml volumes of the dilutions were spread on antibiotic-free Trypticase soy agar plates. The MBC was defined as the lowest concentration of antibiotic that gave >99.9% reduction of the inoculum.
13-Lactamase assays. The ,-lactamases from various bacterial strains were purified as reported previously (6) P-Lactamase studies. The susceptibilities of SCE-2787 and the reference P-lactam antibiotics to hydrolysis by 11 commonly encountered 1-lactamases were examined by determining their relative rates of hydrolysis (Table 3) . SCE-2787 was highly resistant to hydrolysis by plasmid-mediated penicillinases (Bush group 2) and chromosomal cephalosporinases (Bush group 1) from Enterobacter cloacae, Citrobacter freundii, and Pseudomonas aeruginosa, as were ceftazidime and cefpirome. However, SCE-2787, like cefpirome, was hydrolyzed to some extent by some types of 1-lactamases. The comparative stabilities of SCE-2787 and cefpirome varied depending on the type of 1-lactamase; SCE-2787 was hydrolyzed at a lower rate than cefpirome was by the plasmid-mediated group 2d (OXA-1) 1-lactamase and the chromosomally mediated penicillinase (group 2b') from Klebsiella oxytoca, but it was hydrolyzed at a higher To examine the affinity of P-lactamases for SCE-2787, Km or Ki values were also determined and compared with those for ceftazidime ( Table 4 ). All of the Km or Ki values for SCE-2787 of the 1-lactamases tested were >100 ,uM, and these values were as high as or higher than those for ceftazidime, with the exception of the values for the two oxyimino-cephalosporinases.
In vivo efficacy. The protective effects of SCE-2787 against experimental systemic infections with 11 strains of various bacteria in mice are shown in Table 5 . SCE-2787 was more effective than ceftazidime against the infections with Staphylococcus aureus 308A-1, methicillin-resistant Staphylococcus aureus N133A, Escherichia coli 0-111 and T7, Citrobacter freundii TN518, Enterobacter cloacae N-9-201, and Pseudomonas aeruginosa P9 and was more effective than cefpirome against the infections with methicillin-resistant Staphylococcus aureus N133A and Pseudomonas aeruginosa P9, GN3407, and NC-5. The in vivo activities of SCE-2787 against the infections with three strains of Pseudomonas aeruginosa were comparable to those of E1040. SCE-2787 was also as effective as ceftazidime and cefpirome against the infections with Streptococcus pneumoniae type 1 and Haemophilus influenzae H73. DISCUSSION Chemical modifications of cephalosporins have produced a large number of useful antibacterial agents, but it has been difficult to achieve increased activity simultaneously against Staphylococcus species and Pseudomonas aeruginosa (14) . In comparison with ceftazidime, flomoxef, cefpirome, and E1040, SCE-2787 had activity comparable to those of flomoxef and cefpirome against Staphylococcus species and comparable to that of ceftazidime against Pseudomonas aeruginosa. In addition, SCE-2787 had activity comparable to that of cefpirome against Streptococcus species, members of the family Enterobacteriaceae except Proteus vulgaris, although it was only two-to eightfold more active than ceftazidime against ceftazidime-susceptible isolates. There are a number of reports indicating that multiple ,3-lactamresistant mutants emerge rapidly in Citrobacter and Enterobacter species during therapy with broad-spectrum cephalosporins, such as cefotaxime and ceftazidime, and that the emergence of such resistance is responsible for therapeutic failures and relapses of infection (11, 22) . These organisms possess inducible, chromosomal 1-lactamases which are classified as Bush group 1 (1), and the rapid development of resistance has been shown to be closely associated with spontaneous mutation of wild-type organisms to a stably derepressed state for P-lactamase production (11, 21) . The overproduction of group 1 P-lactamases by mutation leads to P-lactam resistance by nonhydrolytic trapping, slow but definite hydrolysis, or both (21) . SCE-2787, like ceftazidime, was resistant to hydrolysis by the Bush group 1 13-lactamases (1) from Citrobacterfreundii, Enterobacter cloacae, Serratia marcescens, and Pseudomonas aeruginosa; but these P-lactamases had lower affinities for SCE-2787 compared with their affinities for ceftazidime. The lower affinity of the ,-lactamases is likely to result in less interaction of SCE-2787 with these enzymes and, thus, less limitation of access to the target sites. Therefore, the good activity of SCE-2787 against Bush group 1 P-lactamase-producing bacteria may be related to low affinity, coupled with resistance to enzymatic hydrolysis, and may diminish the risk of selecting resistance during therapy of Citrobacter and Enterobacter infections. A similar correlation between the activity and the affinity of 3-lactamases has been reported for cefepime (20) , cefpirome (10) , and E1040 (26) . An additional notable feature of SCE-2787 was its moderate activity against methicillin-resistant isolates of Staphylococcus species, especially Staphylococcus epidermidis. It is well-known that methicillin resistance in staphylococci is associated with the production of a unique penicillin-binding protein (PBP 2' or PBP 2a) which has a low binding affinity for ,-lactam antibiotics (5). Our preliminary study has shown that the affinity of PBP 2' for SCE-2787 is clearly higher than that for flomoxef (7) . Therefore, this may be one of the reasons for the moderate activity of SCE-2787 against methicillin-resistant staphylococci. However, other factors also should be taken into account, and in vitro potency alone does not guarantee the clinical utility of ,-lactam antibiotics against methicillin-resistant staphylococci.
The comparative protective efficacies of SCE-2787 and the reference antibiotics against systemic infections caused by various gram-positive and gram-negative bacteria in mice were well correlated with their in vitro activities. SCE-2787 has been shown to have pharmacokinetic properties in mice that are very similar to those of ceftazidime, cefpirome, and E-1040 (9) . Therefore, the in vivo efficacy of SCE-2787 is thought to be mainly due to its potent antibacterial activity.
The results for SCE-2787 obtained in this study indicate that the compound is a very promising new parenteral cephalosporin for the treatment of infections caused by a variety of gram-positive and gram-negative bacteria. SCE-2787 is in clinical trials.
